Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tenecteplase for treatment of acute myocardial infarction
Autore:
Turcasso, NM; Nappi, JM;
Indirizzi:
Med Univ S Carolina, Dept Pharm Practice, Coll Pharm, Charleston, SC 29425USA Med Univ S Carolina Charleston SC USA 29425 harm, Charleston, SC 29425USA Med Univ S Carolina, Drug Informat Ctr, Charleston, SC 29425 USA Med Univ S Carolina Charleston SC USA 29425 Ctr, Charleston, SC 29425 USA Med Univ S Carolina, Coll Pharm, Charleston, SC 29425 USA Med Univ S Carolina Charleston SC USA 29425 arm, Charleston, SC 29425 USA
Titolo Testata:
ANNALS OF PHARMACOTHERAPY
fascicolo: 10, volume: 35, anno: 2001,
pagine: 1233 - 1240
SICI:
1060-0280(200110)35:10<1233:TFTOAM>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
TISSUE-PLASMINOGEN-ACTIVATOR; ALTEPLASE; BOLUS; TRIAL; THROMBOLYSIS; RETEPLASE;
Keywords:
acute myocardial infarction; tenecteplase;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Turcasso, NM Med Univ S Carolina, Dept Pharm Practice, Coll Pharm, 150 Ashley Ave,Rm 604,Rutledge Tower Annex, Charleston, SC 29425 USA Med Univ S Carolina 150 Ashley Ave,Rm 604,Rutledge Tower Annex Charleston SC USA 29425
Citazione:
N.M. Turcasso e J.M. Nappi, "Tenecteplase for treatment of acute myocardial infarction", ANN PHARMAC, 35(10), 2001, pp. 1233-1240

Abstract

OBJECTIVE: To describe the pharmacology, pharmacokinetics, efficacy; and safety of tenecteplase in reducing mortality associated with acute myocardial infarction (AMI). DATA SOURCES: Published articles were identified from MEDLINE (from 1966 to December 2000) and Current Contents (all sections) searches. STUDY SELECTION AND DATA EXTRACTION. Dose-ranging and pivotal studies wereincluded for analysis in the clinical trials section. DATA SYNTHESIS: Tenecteplase is a third-generation thrombolytic indicated for the reduction of mortality associated with AMI. Tenecteplase has a longer half-life that allows for single-dose, intravenous bolus administration. Data from clinical trials support that tenecteplase is similar to alteplase in reducing 30-day mortality rates in patients who have had an AMI. In the ASSENT-2 (Assessment of the Safety and Efficacy of a New Thrombolytic) trial, patients treated with tenecteplase required fewer blood transfusions and experienced fewer episodes of noncerebral bleeding compared with those treated with alteplase. CONCLUSIONS: Tenecteplase is an effective thrombolytic agent for the treatment of AML It can be given as a single weight-based dose; however, it appears to offer no significant advantage over other agents in terms of its efficacy or rate of intracranial hemorrhage.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:49:37